Completed PHASE2 INTERVENTIONAL NCT00425503

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

H-11047: A Study of PS-341 Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate (Spore #: 11-01-30-13)

Sponsor: Baylor College of Medicine

Conditions Prostate Neoplasms

Interventions PS-341 (bortezomib)

Updated 6 times since 2017 Last updated: Apr 3, 2014 Started: Dec 31, 2001 Primary completion: Nov 30, 2012 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Prostate Neoplasms, this trial is completed. The trial is conducted by Baylor College of Medicine and has accumulated 6 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor College of Medicine
Millennium Pharmaceuticals, Inc.

Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States